Travere Therapeutics, Inc. - 8-K Filing
Travere Therapeutics entered into a $112.5 million upfront payment license agreement with Everest Medicines for exclusive rights to develop and commercialize civorebrutinib, a BTK inhibitor, outside of China and certain East/Southeast Asian countries. The deal includes up to $1.03 billion in potential milestone payments and tiered royalties on net sales. (Items: 1.01 Entry into a Material Definitive Agreement, 9.01 Financial Statements and Exhibits)
Tickers: $TVTX